



Around the world of U.S. healthcare in 360 words or less



March 10, 2025 | Issue 360

Editor's note

[This series](#) is produced by KPMG Healthcare and is intended to be short and succinct, less than 360 words, to provide a weekly digestible bite of healthcare regulatory, policy, and industry news relevant to our clients. Links are provided to source material (proposed and final regulations, agency guidance and press releases, reports, research, etc.) when available. Please share this email with colleagues and other interested individuals, and encourage them to [subscribe to our mailing list here](#).

We welcome your feedback. Let us know if KPMG can help. Please reply to this email with any comments or requests.

[> Subscribe here](#)



Healthcare regulatory news

HHS is [rolling back](#) a 1971 policy that required the agency to undergo notice and comment rulemaking for issues pertaining to “agency management or personnel or to public property, loans, grants, benefits, or contracts.” Reports [suggest](#) that the policy change could apply to rules about NIH grants and the Medicaid program.

CMS [rescinded guidance](#) on coverage for services that address health-related social needs in Medicaid and CHIP via [Section 1115 waivers](#), opting instead to evaluate states’ applications for these services on a case-by-case basis.



Healthcare law and policy news

The Senate Finance Committee [scheduled](#) a confirmation hearing on March 14 for Dr. Mehmet Oz to serve as CMS Administrator.

Growth in Medicare Advantage (MA) enrollment has slowed in 2025, compared to the same period in 2024, according to [recently released data](#) from CMS... While MA has experienced [consistent year-over-year growth](#) since 2007, expansion has been more modest in recent years as the MA penetration rate now exceeds 50% of Medicare beneficiaries.

A federal judge issued a [nationwide injunction](#) pausing NIH funding cuts proposed by the Trump administration, which would stipulate a 15% cap on “indirect costs” for overhead and administrative expenses.

Federal health officials are working to curb measles outbreaks in Texas and New Mexico, according to a new [statement](#) from the CDC. HHS said it continues to provide technical assistance, lab support, vaccines, and medication, as [reports indicate](#) that cases are growing.

[Bipartisan legislation](#) introduced in the House of Representatives would modify provisions of the Inflation Reduction Act (IRA) to provide parity for the timing requirements under which small-molecule drugs and biological products are eligible for negotiation.

The House [passed](#) the [Chronic Disease Flexibility Act](#) in alignment with 2019 Trump administration guidance allowing flexible coverage options for healthcare services through high-deductible health plans (HDHPs). The legislation would permit expanded coverage for certain chronic disease medical products and services, including blood pressure monitors, glucometers, etc.

Novo Nordisk [plans to investigate](#) if its GLP-1 drugs may also support addiction treatment. Clinical trials [have already begun studying](#) the use of GLP-1s to treat alcohol and tobacco use disorders.





Questions or comments, please send
to us-hclspractice@kpmg.com.

kpmg.com/socialmedia



[Privacy](#) | [Legal](#)

You have received this message from KPMG LLP. If you wish to unsubscribe from Around the world of U.S. healthcare in 360 words or less, please [click here](#). If you wish to unsubscribe from all KPMG communications, please [click here](#).

KPMG LLP, 3 Chestnut Ridge Road, Montvale, NJ 07645

© 2024 KPMG LLP, a Delaware limited liability partnership and a member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved.
USCS011380-1B

The KPMG name and logo are trademarks used under license by the independent member firms of the KPMG global organization.